Renovo Concepts, Inc., a San Antonio, TX-based early-stage medical device company, closed an approximately $6.4m Series A funding round.
The backers were not disclosed.
The company intends to use the funds for final product development, initial manufacturing and First-In-Human (safety) study for their proprietary Mechanical Tissue Resuscitation (MTRTM) device, for use in the treatment of Traumatic Brain Injury
Led by Mark Standeford, Chief Executive Officer, Renovo was formed in 2017 to develop and commercialize the Mechanical Tissue Resuscitation (MTRTM) device.
Developed and researched at the Wake Forest School of Medicine by Dr. Louis Argenta, MD and Michael Morykwas, Ph.D., Mechanical Tissue Resuscitation (MTRTM) has shown promising results treating traumatic, ischemic and hemorrhagic injuries to the brain, heart and spinal cord. The MTRTM patent estate has been licensed exclusively to Renovo by Wake Forest for use in each of the above-described areas.